← All trials
NCT05699005
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2023
- Primary completion
- Jan 1, 2025
- Completion date
- Jan 1, 2025
- First posted
- Jan 26, 2023
- Last posted
- Jan 26, 2023
- Enrollment
- 238
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LilleLead sponsor
- University of Picardie Jules VerneCollaborator
- Centre Hospitalier de LensCollaborator
- University of BurgundyCollaborator
- University of Caen-NormandieCollaborator
- University of LilleOverall official - principal investigator
- Rouen Normandy UniversityCollaborator
- University of LilleOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.